Literature DB >> 2748531

Kinetics of drug action in disease states. XXXI. Effect of experimental hyperthyroidism on the hypnotic activity of a benzodiazepine (oxazepam) in rats.

J S Walker1, P M Klockowski, G Levy.   

Abstract

This investigation was designed to determine the effect of experimental hyperthyroidism on the hypnotic activity of a benzodiazepine and on the binding characteristics of the benzodiazepine receptor complex. Rats were made hyperthyroid by subcutaneous implantation of slow release pellets containing L-thyroxine. This treatment produced the characteristic symptoms of hyperthyroidism: increased serum thyroxine concentrations, increased heart weight and body temperature, and decreased serum protein concentrations. The hyperthyroid rats and a parallel group of normal animals (with drug-free pellets implanted subcutaneously) were slowly infused intravenously with oxazepam until they lost their righting reflex. The hyperthyroid rats required a significantly larger dose of the benzodiazepine and their total serum and cerebrospinal fluid concentrations of oxazepam (but not the serum concentration of free drug and the brain concentration) at the onset of loss of the righting reflex were modestly but statistically significantly lower than those of the normal rats. The receptor density and affinity for diazepam in hyperthyroid rats were not significantly different from those of the normal animals. Hyperthyroidism apparently affects the pharmacokinetics of oxazepam but has, at best, only a small effect on the pharmacodynamics (hypnotic activity) of the drug.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2748531     DOI: 10.1023/a:1015983415887

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  15 in total

1.  Kinetics of drug action in disease states. XXIV. Pharmacodynamics of diazepam and its active metabolites in rats.

Authors:  P M Klockowski; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1988-03       Impact factor: 4.030

2.  Barbiturate mortality in hypothyroid and hyperthyroid rats.

Authors:  R D Harbison; B A Becker
Journal:  J Pharm Sci       Date:  1969-02       Impact factor: 3.534

3.  Thyroid hormones and derivatives inhibit flunitrazepam binding.

Authors:  A Nagy; A Lajtha
Journal:  J Neurochem       Date:  1983-02       Impact factor: 5.372

4.  Thyroid hormones do not alter rat brain benzodiazepine receptor function in-vivo.

Authors:  C K Atterwill; D J Nutt
Journal:  J Pharm Pharmacol       Date:  1983-11       Impact factor: 3.765

5.  Benzodiazepine receptor and thyroid hormones: in vivo and in vitro modulation.

Authors:  J H Medina; E De Robertis
Journal:  J Neurochem       Date:  1985-05       Impact factor: 5.372

6.  Brain receptor binding and lipophilic character of benzodiazepines.

Authors:  P A Borea; A Bonora
Journal:  Biochem Pharmacol       Date:  1983-02-15       Impact factor: 5.858

7.  Oxazepam pharmacokinetics in thyroid disease.

Authors:  A K Scott; A S Khir; P D Bewsher; G M Hawksworth
Journal:  Br J Clin Pharmacol       Date:  1984-01       Impact factor: 4.335

8.  Pharmacokinetic modeling of the anticonvulsant response of oxazepam in rats using the pentylenetetrazol threshold concentration as pharmacodynamic measure.

Authors:  J Dingemanse; F A Sollie; D D Breimer; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1988-04

9.  Kinetics of drug action in disease states. XXV. Effect of experimental hypovolemia on the pharmacodynamics and pharmacokinetics of desmethyldiazepam.

Authors:  P M Klockowski; G Levy
Journal:  J Pharmacol Exp Ther       Date:  1988-05       Impact factor: 4.030

Review 10.  Could an endogenous benzodiazepine ligand contribute to hepatic encephalopathy?

Authors:  K D Mullen; J V Martin; W B Mendelson; M L Bassett; E A Jones
Journal:  Lancet       Date:  1988-02-27       Impact factor: 79.321

View more
  1 in total

1.  Kinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.

Authors:  Meindert Danhof
Journal:  J Pharmacokinet Pharmacodyn       Date:  2015-08-30       Impact factor: 2.745

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.